Aquestive Therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. Our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. Our initial focus, supported by our current approved products and late stage pipeline, is to address immediate CNS challenges.
Location: United States, New Jersey
Employees: 51-200
Investors 1
| Date | Name | Website |
| - | Perceptive... | perceptive... |
Mentions in press and media 9
| Date | Title | Description |
| 11.11.2025 | Cramer’s Lighting Round: ‘You want to stay in’ Amphenol | Monday - Friday, 6:00 - 7:00 PM ET It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed. Amphenol: “It’s just such a great stock...Y... |
| 09.05.2025 | Biosergen Nomination Committee Proposes New Board Member with an Extensive Tracking Record in the Development, Commercialization and Out-Licensing of Anti-Infectives | Biosergen Nomination Committee Proposes New Board Member with an Extensive Tracking Record in the Development, Commercialization and Out-Licensing of Anti-Infectives Fri, May 09, 2025 15:14 CET Report this content Stockholm, Sweden – May 9,... |
| 19.03.2024 | Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock | - |
| 05.03.2024 | Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update | - |
| 02.11.2023 | Aquestive Therapeutics Completes $45 Million Debt Refinancing | - |
| 08.06.2022 | Aquestive Therapeutics, Inc. Announces Closing of $8.5 Million Registered Direct Offering | WARREN, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to impr... |
| 06.06.2022 | Aquestive Therapeutics, Inc. Announces $8.5 Million Registered Direct Offering | WARREN, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to impr... |
| 25.11.2019 | Aquestive nabs FDA OK for oral film version of generic ALS drug | The FDA has given Aquestive Therapeutics the green light to market Exservan, its oral film formulation of a decades-old treatment for amyotrophic lateral sclerosis. Keith Kendall Back in 1995 riluzole became the first F... |
| 28.06.2018 | Term Sheet — Thursday, June 28 | LYFTED Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop Here are some additional notes: • In total, Lyft has raised $5.1 billion in funding. Lyft’s investors include AllianceBernstein, Baillie... |